Oncolytics Biotech Announces New Three-Arm Phase III Clinical Trial for Pelareorep in First-Line Pancreatic Cancer
I'm PortAI, I can summarize articles.
Oncolytics Biotech Inc. has announced a new three-arm Phase III clinical trial for pelareorep in first-line pancreatic cancer. The trial will randomize patients to receive either standard chemotherapy or chemotherapy combined with pelareorep, with the primary endpoint being overall survival. The company plans to meet with the FDA in mid-November 2025 to discuss the study details. An interim efficacy analysis will be conducted during the trial. Results from this trial have not yet been presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments